Centre for Addiction and Mental Health
Toronto, Ontario, M5T 1R8, Canada
NCT Number: NCT04379349
Engagement with clinical services for youth with early psychosis represents a significant challenge, with up to 40% of patients dropping out of treatment in the first year. This has been linked to worse illness outcomes and represents a significant barrier to recovery for these patients. This study aims to evaluate the efficacy of short message service (SMS) as a means of improving clinical engagement in early-episode psychosis populations by bridging contact between appointments with weekly check-ins/reminders. These weekly check-ins during the first year of treatment will serve as an additional opportunity to reach out to patients and give them a chance to do the same with their care teams, with patient responses triggering clinician follow-up if necessary.
Looking for future studies?
Notify Me16 year–29 year
All sexes
Interventional
Not applicable
Toronto, Ontario, M5T 1R8, Canada
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Interactive SMS text message check-ins delivered once weekly to participants.
Minimally interactive SMS text message delivered once weekly to participants.
Time frame: 9 months
Clinician-rated treatment engagement and adherence (minimum score = 0, maximum score = 42, higher score indicates worse service engagement)
Time frame: 9 months
Percentage of attended clinic appointments
Time frame: 9 months
Number of emergency department visits
Time frame: 9 months
Number of hospitalizations
Time frame: 9 months
Self-report measure of social functioning (minimum score = 0, maximum score = 247, higher score indicates better functioning)
Time frame: 9 months
Interview-rated measure of global functioning (minimum score = 1, maximum score = 100, higher score indicates better functioning)
Time frame: 9 months
Self-reported measure of subjective quality of life (minimum score = 1, maximum score = 5, higher score indicates better quality of life)
Time frame: 9 months
Interview-based global rating of illness severity (minimum score = 1, maximum score = 7, higher score indicates worse illness severity)
Time frame: 9 months
Interview-based measure of the severity of psychiatric symptoms (minimum score = 24, maximum score = 168, higher score indicates higher severity of symptoms)
Time frame: 9 months
Interview-based measure of the severity of negative symptoms (minimum score = 0, maximum score = 110, higher score indicates higher severity of symptoms)
Time frame: 9 months
Interview-rated measure of the severity of motivation deficits (minimum score = 18, maximum score = 72, higher score indicates worse motivation deficits)
Time frame: 9 months
Rater-administered measure of cognitive functioning (scores indicate standardized Z-scores with no pre-defined minimum or maximum score, higher score indicates better cognitive functioning)
Time frame: 9 months
Self-reported measure of medication adherence (minimum score = -10, maximum score = + 10, higher score indicates better adherence)
Time frame: 9 months
Self-reported measure of the clinician-patient therapeutic relationship (minimum score = 0, maximum score = 48, higher score indicates better therapeutic relationship)
Centre for Addiction and Mental Health
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06186570
Hallucinations, Mental Disorders
Berlin, State of Berlin, Germany
View Trial DetailsNCT05813080
Cognition Disorders, Mental Disorders
Konstanz, Baden-Wurttemberg, Germany
View Trial DetailsNCT06410508
Behavior, Engagement, Patient
Halifax, Nova Scotia, Canada
View Trial DetailsNCT04602741
Mental Disorders, Psychotic Disorders
Toronto, Ontario, Canada
View Trial Details